Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy
Background: Market access stakeholders consider the adoption of Managed Entry Agreements (MEAs), however a clearly described methodology to quantify their implementation burden is not available in the public domain. Objective: To quantify the cost of implementing a performance-based MEA at the hospi...
Saved in:
| Main Authors: | Panos Kefalas, Omar Ali, Jesper Jørgensen, Nick Merryfield, Tim Richardson, Adam Meads, Laura Mungapen, Matthew Durdy |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-01-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20016689.2018.1511679 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test
by: Jesper Jørgensen, et al.
Published: (2017-01-01) -
Delayed access to innovative medicines in Romania: a comprehensive analysis of the reimbursement processes (2015–2024)
by: Constantin Radu, et al.
Published: (2025-05-01) -
Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching
by: Jesper Jørgensen, et al.
Published: (2019-01-01) -
Policy guidelines for risk-sharing agreements in South Africa
by: Joao L. Carapinha
Published: (2008-10-01) -
Real-World Evidence and Managed Entry Agreements
by: Silvia Adami, et al.
Published: (2025-07-01)